You are here: Industry Insights > Cosentyx

News List

Lilly’s mirikizumab superior to Cosentyx in phase 3 study for patients with moderate to severe plaque psoriasis pharmaceutical-business-review
July 22, 2020
Eli Lilly and Company announced that mirikizumab, an investigational monoclonal antibody that binds to the p19-subunit of IL23, met the primary and all key secondary endpoints versus placebo at Week 16 (superiority) and ...
Cosentyx Gains Positive CHMP Opinion for Pediatric Psoriasis americanpharmaceuticalreview
July 08, 2020
Novartis announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion for Cosentyx® (secukinumab) for the treatment of moderate-to-severe plaque psoriasis in children and ...
Cosentyx Receives FDA Approval for New Indication americanpharmaceuticalreview
June 29, 2020
Novartis announced the US Food and Drug Administration (FDA) has approved Cosentyx® (secukinumab) for the treatment of active non-radiographic axial spondyloarthritis (nr-axSpA).
Novartis gets FDA approval for Cosentyx to treat active non-radiographic axial spondyloarthritis pharmaceutical-business-review
June 22, 2020
Novartis has secured approval from the US Food and Drug Administration (FDA) for its Cosentyx (secukinumab) to treat active non-radiographic axial spondyloarthritis (nr-axSpA).
Cosentyx Gains Fourth indication in EU for Axial Spondyloarthritis Spectrum americanpharmaceuticalreview
May 05, 2020
Novartis announced the European Commission (EC) has approved Cosentyx® (secukinumab) for the treatment of adult patients with active non-radiographic axial spondyloarthritis (nr-axSpA).
Novartis gets positive CHMP opinion for Zolgensma and Cosentyx pharmaceutical-technology
March 31, 2020
Novartis has received a positive opinion from the European Medicines Agency (EMA)’s Committee for Medicinal Products for Human Use (CHMP) for Zolgensma in spinal muscular atrophy (SMA), and Cosentyx in non-radiographic axial spondyloarthritis (nr-axSpA).
Cosentyx® (secukinumab) meets clinical trial endpoints europeanpharmaceuticalreview
September 19, 2019
Cosentyx®, a treatment for an inflammatory disease has met its primary endpoints in patients during a Phase III trial.
Cosentyx, Entresto again drive growth at Novartis. But what about the future of Zolgensma? fiercepharma
April 25, 2019
The future of Novartis’ potential blockbuster spinal muscular atrophy gene therapy Zolgensma has come under question, what with a recent child death reported in the company's European trial.
Novartis lifts annual profit outlook as Cosentyx, Entresto lead first-quarter sales growth firstwordpharma
April 25, 2019
Novartis is off to a strong start in 2019 with the Mayzent launch, successful Alcon spin-off and strong operational execution leading us to revise 2019 profit guidance upwards ...
FDA approves the inclusion of new evidence for Cosentyx in PsA europeanpharmaceuticalreview
April 25, 2019
The FDA has approved the inclusion of new evidence that Cosentyx significantly slows the progression of joint structural damage...

Previous page 1 2 3 4 Next page